We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

133 hedge funds and large institutions have $385M invested in Progenics Pharmaceuticals Inc in 2015 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 43 increasing their positions, 43 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 12

29% more call options, than puts

Call options by funds: $1.14M | Put options by funds: $886K

10% more funds holding

Funds holding: 121133 (+12)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 43

23% less capital invested

Capital invested by funds: $501M → $385M (-$116M)

Holders
133
Holders Change
+12
Holders Change %
+9.92%
% of All Funds
3.71%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
24
Increased
43
Reduced
43
Closed
12
Calls
$1.14M
Puts
$886K
Net Calls
+$254K
Net Calls Change
-$1.04M
Name Holding Trade Value Shares
Change
Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$77.3M
BC
2
Broadfin Capital
New York
$51.2M
Fidelity Investments
3
Fidelity Investments
Massachusetts
$30.5M +$690K +89,872 +2%
State Street
4
State Street
Massachusetts
$25.7M -$3.4M -442,887 -9%
BBA
5
Baker Bros. Advisors
New York
$24.9M
RA
6
Royce & Associates
New York
$17M -$1.86M -242,900 -8%
BFA
7
BlackRock Fund Advisors
California
$16.2M +$767K +99,942 +4%
Tudor Investment Corp
8
Tudor Investment Corp
Connecticut
$13.7M +$33.7K +4,391 +0.2%
Vanguard Group
9
Vanguard Group
Pennsylvania
$13.4M +$560K +72,979 +3%
Millennium Management
10
Millennium Management
New York
$13M +$2.12M +275,897 +14%
BIT
11
BlackRock Institutional Trust
California
$10.4M -$1.61M -209,436 -10%
Wellington Management Group
12
Wellington Management Group
Massachusetts
$4.87M -$6.12M -798,193 -48%
BIM
13
Bogle Investment Management
Massachusetts
$4.52M +$6.06M +790,381 New
Northern Trust
14
Northern Trust
Illinois
$4.44M +$376K +48,987 +7%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$3.77M
Bank of New York Mellon
16
Bank of New York Mellon
New York
$3.66M +$806K +105,074 +20%
KCM
17
Kennedy Capital Management
Missouri
$3.56M +$3.05M +397,775 +177%
NI
18
Numeric Investors
Massachusetts
$3.47M +$1.2M +156,842 +35%
PFC
19
Phocas Financial Corp
California
$3.37M +$312K +40,632 +7%
Fuller & Thaler Asset Management
20
Fuller & Thaler Asset Management
California
$3.31M +$3.07K +400 +0.1%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$2.97M +$634K +82,627 +19%
RHJA
22
Rice Hall James & Associates
California
$2.76M +$3.23M +421,104 +691%
Deutsche Bank
23
Deutsche Bank
Germany
$2.75M +$1.72M +224,320 +87%
GCP
24
GSA Capital Partners
United Kingdom
$2.73M +$1.26M +164,034 +52%
EI
25
EAM Investors
California
$2.53M -$1.76M -229,770 -34%

PGNX Hedge Fund Activity: Q3 2015 in Review

133 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2015, worth a combined $385M — down 23% from $501M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new PGNX positions and 12 closed out — a net gain of 12 holders — while 43 added to existing stakes and 43 trimmed.

The largest buyer was Bogle Investment Management, opening a new position worth an estimated $6.06M. The largest seller was Wellington Management Group, cutting an estimated $6.12M.

  • 133 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2015, up from 121 in Q2 2015.
  • Funds reported $385M of Progenics Pharmaceuticals Inc stock for Q3 2015, down 23% quarter-over-quarter.
  • 24 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2015 and 12 closed out, a net change of +12 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q3 2015 was Bogle Investment Management, an estimated $6.06M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q3 2015 was Wellington Management Group, an estimated $6.12M sold.

Based on aggregated 13F filings for Q3 2015.